Clinical Trial Update: Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating safety, tolerability, and effects of PF-05175157 in adults with moderate to severe acne vulgaris has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• PF-05175157

Snippet

Sponsor: Pfizer | Conditions: Acne Vulgaris | Phase 2 | Status: WITHDRAWN